首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1295386

移植免疫抑製劑市場 - 預測 2023-2028

Transplant Immunosuppressive Drug Market - Forecasts from 2023 to 2028

出版日期: 2023年06月08日 | 出版商:

Knowledge Sourcing Intelligence | 英文 113 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

移植免疫抑製劑市場預計將從2021年的90.96億美元增至2028年的145.1億美元，預測期內復合年增長率為6.90%。

移植技術的最新進展，包括微創手術和改進的移植後護理，提高了器官移植的成功率。因此，對移植免疫抑製劑的需求不斷增長，以維持移植器官的活力並防止排斥反應。

這些藥物有助於保護患者免受移植的外來器官的排斥。此外，心血管疾病、糖尿病、癌症和哮喘等慢性病患病率的上升預計將增加對器官移植的需求，從而在預測期內進一步推動移植免疫抑製劑市場的發展。

藥物研究和開發的重大進展導致了新型和改進的移植免疫抑製劑的推出。這些藥物旨在提高療效、最大限度地減少副作用並改善患者的治療結果，從而推動市場增長。此外，老齡化社會更容易出現器官衰竭和慢性疾病，增加了對器官移植的需求。隨著全球老年人口的增加，移植免疫抑製劑市場預計將進一步擴大。

推動市場增長的主要原因之一是器官移植手術數量的增加。

據衛生資源和服務管理局稱，2022 年將進行超過 42,000 例移植手術，其中包括 25,499 例腎臟、9,528 例肝臟、108 例胰腺、4,111 例心臟和 2,692 例其他移植。

外科技術的進步提高了器官移植手術的成功率，使其成為一種更安全、更可行的治療方法。微創手術、腹腔鏡技術以及活體移植和配對器官交換計劃等創新移植方法正在擴大可用器官庫並增加手術數量。此外，政府、醫療保健組織和非營利組織還建立了專門的計劃和網絡來促進和便利器官移植。這些舉措的重點是建立有效的器官分配系統、改善移植基礎設施以及提高器官捐贈的意識。例如，美國器官移植網絡（UNOS）幫助管理器官移植系統並協調器官分配。

器官移植領域預計將佔據較大的市場份額。

移植免疫抑製劑市場按移植類型分為組織移植和器官移植。根據衛生資源和服務管理局 2023 年 1 月收集的數據，共有 25,499 例腎臟移植手術，而肝臟移植手術為 9,528 例，心臟移植手術為 4,111 例，肺移植手術為 2,692 例。圖中的其他移植物包括同種異體移植物，例如面部、手部和腹壁。

從地區來看，移植免疫抑製劑市場分為北美、南美、歐洲、中東和非洲以及亞太地區。組織工程市場的發展、醫療成本的上升以及器官移植手術的增加正在推動北美移植免疫抑製劑市場的增長。

根據聯合國器官共享網絡（UNOS）提供的數據顯示，2022年美國進行的器官移植手術總數為42,887例，比2021年的手術數量增長了3.7%。此外，根據同一消息來源，2022年進行了25,498例腎移植手術，比2021年增加了3.4%。器官移植手術的增加將對美國移植免疫抑製劑的需求產生積極影響，加速市場增長。

市場趨勢：

2021 年 7 月，美國食品和藥物管理局批准 Astella Inc. 的 PROGRAF(R) 用於在美國接受肺、肝、腎和心臟移植的患者。同樣在 2020 年 12 月，美國參議院通過了一項免疫抑製劑法案，擴大了腎移植受者的醫療保險覆蓋範圍。通過延長醫療保險，患者將可以獲得所有救生藥物。
2022年8月，印度Concord Biotech Limited向市場監管機構印度證券交易委員會（SEBI）提交了一份DRHP（Draft Red Herring Prospectus），擬通過首次公開募股（IPO）籌集資金。
2022年9月，Strides的環孢素軟膠囊獲得美國FDA批准。隨著他克莫司膠囊、環孢素軟膠囊以及嗎替麥考酚酯片劑和膠囊添加到其針對美國市場的免疫抑製劑產品組合中，Strides 進一步鞏固了其在市場上的地位。
2022年9月，中東和非洲開羅與外國公司合作開設器官移植中心。該器官移植設施包括移植物、患者和捐贈者的自動化數據庫。
2022年9月，卡納塔克邦國家器官和組織移植組織（SOTTO）獲得印度中央政府的正式批准，以促進該地區的器官捐獻。該計劃已批准 840 萬印度盧比（101,000 美元）的預算。

The market in recent times has been witnessing advancements in transplantation techniques, including minimally invasive procedures and improved post-transplant care, which have increased the success rates of organ transplants. This has led to a higher demand for transplant immunosuppressive drugs to maintain the viability of transplanted organs and prevent rejection.

These drugs help protect patients against rejection of the transplanted foreign organ by their bodies. Moreover, the rising prevalence of chronic diseases such as cardiovascular disease, diabetes, cancer, and asthma is expected to increase the demand for organ transplants, further boosting the transplant immunosuppressive drugs market during the forecast period.

Significant advancements in pharmaceutical research and development have led to the introduction of new and improved transplant immunosuppressive drugs. These drugs are designed to enhance efficacy, minimize side effects, and improve patient outcomes, driving market growth. Moreover, the aging population is more prone to organ failure and chronic diseases, leading to a higher demand for organ transplantation. As the geriatric population grows globally, the transplant immunosuppressive drugs market is expected to expand further.

One of the primary reasons driving the market's growth is the increased number of organ transplant surgeries.

According to the health resources and services administration, 42,000+ transplants were performed in 2022, out of which 25,499 were for kidneys, 9,528 were for the liver, 108 were for the pancreas, 4,111 were for the heart, and 2,692 were for others.

Advancements in surgical techniques have improved the success rates of organ transplant surgeries, making them safer and more viable treatment options. Minimally invasive procedures, laparoscopic techniques, and innovative transplant approaches, such as living donor transplants and paired organ exchange programs, have expanded the pool of available organs and increased the number of surgeries performed. Furthermore, governments, healthcare organizations, and non-profit organizations have established dedicated programs and networks to promote and facilitate organ transplantation. These initiatives focus on creating efficient organ allocation systems, improving transplantation infrastructure, and increasing awareness about organ donation. For example, the United Network for Organ Sharing (UNOS) in the United States manages the organ transplant system and helps coordinate the allocation of organs.

The organ transplantation segment will constitute a significant market share.

The transplant immunosuppressive drug market is segmented by transplant type into tissue and organ transplantation. According to the data collected by health resources and service administration on January 2023, there were 25,499 kidney transplants, whereas 9,528 liver transplants and heart and lung transplants were 4,111 and 2,692, respectively. Other transplants in the graph include allograft transplants like the face, hands, and abdominal wall.

The transplant immunosuppressive drugs market, by geography, is analyzed into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The development in tissue engineering and growing expenditure on healthcare, coupled with the increase in organ transplant surgeries, are driving the market growth for transplant immunosuppressive drugs in North America.

According to the data provided by the United Network for Organ Sharing (UNOS), in 2022, the total number of organ transplant procedures performed in the USA stood at 42,887, which signified an increase of 3.7% in comparison to the number of procedures performed in 2021. Moreover, as per the same source, 25,498 kidney transplant procedures were performed in 2022, representing a 3.4% increase over 2021. Such an increase in organ transplant procedures will positively impact the demand for transplant immunosuppressive drugs in the USA, accelerating market growth.

Market Developments:

In July 2021, the U.S. Food and Drug Administration approved Astella Inc's "PROGRAF®," which would be used in the U.S. for people undergoing lung, liver, kidney, and heart transplants. Also, in December 2020, the U.S. Senate passed immunosuppressive drug legislation to extend Medicare coverage for patients who had undergone kidney transplants. Extended Medicare would enable patients to have access to all the lifesaving medications.
In August 2022, the India-based Concord Biotech Limited, one of the market share leaders in the development and production of specific fermentation-based APIs for immunosuppressants and oncology, filed its Draught Red Herring Prospectus (DRHP) with the markets regulator Securities and Exchange Board of India (SEBI) to raise money through an initial public offering (IPO).
In September 2022, Strides' Cyclosporine Softgel Capsules were given USFDA clearance. With the addition of Tacrolimus capsules, Cyclosporine Softgel capsules, and Mycophenolate Mofetil tablets and capsules to its range of immunosuppressant products for the U.S. market, Strides further solidified its position in the market.
In September 2022, Cairo in the Middle East and Africa opened an organ transplant center in collaboration with foreign businesses. This organ transplant facility includes an automated database for transplants, patients, and donors.
In September 2022, the State Organ Tissue Transplant Organisation (SOTTO) of Karnataka received official recognition from the Indian government's central office to promote organ donation in the region. A budget of INR 84 lakh (USD 101,000) was approved for the program.

Market Segmentation:

By Type

Induction Drugs
Maintenance Drugs

By Transplant Type

Tissue Transplantation
Organ Transplantation

By Geography

North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
UK
Germany
France
Italy
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
Japan
South Korea
India
Indonesia
Thailand
Taiwan
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Research Data
2.3. Validation

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Product Pipeline

5. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY TYPE

5.1. Introduction
5.2. Induction Drugs
5.3. Maintenance Drugs

6. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY TRANSPLANT TYPE

6.1. Introduction
6.2. Tissue Transplantation
6.3. Organ Transplantation

7. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY GEOGRAPHY

7.1. Introduction
7.2. North America
- 7.2.1. By Type
- 7.2.2. By Transplant Type
- 7.2.3. By Country
- 7.2.3.1. United States
- 7.2.3.2. Canada
- 7.2.3.3. Mexico
7.3. South America
- 7.3.1. By Type
- 7.3.2. By Transplant Type
- 7.3.3. By Country
- 7.3.3.1. Brazil
- 7.3.3.2. Argentina
- 7.3.3.3. Others
7.4. Europe
- 7.4.1. By Type
- 7.4.2. By Transplant Type
- 7.4.3. By Country
- 7.4.3.1. UK
- 7.4.3.2. Germany
- 7.4.3.3. France
- 7.4.3.4. Italy
- 7.4.3.5. Spain
- 7.4.3.6. Others
7.5. Middle East and Africa (MEA)
- 7.5.1. By Type
- 7.5.2. By Transplant Type
- 7.5.3. By Country
- 7.5.3.1. Saudi Arabia
- 7.5.3.2. UAE
- 7.5.3.3. Others
7.6. Asia Pacific
- 7.6.1. By Type
- 7.6.2. By Transplant Type
- 7.6.3. By Country
- 7.6.3.1. China
- 7.6.3.2. Japan
- 7.6.3.3. South Korea
- 7.6.3.4. India
- 7.6.3.5. Indonesia
- 7.6.3.6. Thailand
- 7.6.3.7. Taiwan
- 7.6.3.8. Others